

# DEPOFOAM® BUPIVACAINE (DB; EXPAREL™; BUPIVACAINE LIPOSOME EXTENDED-RELEASE INJECTABLE SUSPENSION) EXHIBITS PHARMACOKINETIC PROPERTIES CONSISTENT WITH SUSTAINED-RELEASE CHARACTERISTICS

Deedee Hu<sup>1</sup>; Neil Singla<sup>2</sup>; Lakshmanasamy Somasundaram<sup>3</sup>; Jeff Gadsden<sup>3</sup>; William Kramer<sup>4</sup>; Admir Hadzic<sup>3</sup>

<sup>1</sup>Memorial Hermann Memorial City Medical Center, Houston, TX; <sup>2</sup>Lotus Clinical Research, Inc., Pasadena, CA; <sup>3</sup>St. Luke's Roosevelt Hospital, New York, NY; <sup>4</sup>Kramer Consulting LLC, North Potomac, MD

## ABSTRACT

**Purpose:** Liposomal drug containing formulations are designed to provide slow release of drug over an extended period of time, thus extending duration while diminishing high plasma levels. We conducted a cross-study analysis of the pharmacokinetic properties of DepoFoam Bupivacaine (DB; proposed proprietary name, EXPAREL™), an extended-release multivesicular liposomal formulation of bupivacaine in DepoFoam, given as a single injection.

**Methods:** Pooled data from 446 individuals (age 18–85; 63% male) from eleven Phase 1–3 studies who received either DB or bupivacaine HCl were analyzed for pharmacokinetic parameters including  $T_{max}$ ,  $t_{1/2}$ , and  $C_{max}$ . Routes of administration included wound infiltration, subcutaneous, epidural, and nerve block. Surgical models included hemorrhoidectomy, hemiorrhaphy, bunionectiony, and total knee arthroplasty. Doses ranged from 75–750 mg.

**Results:** DB demonstrated bimodal peak concentrations at 0.25–2 hours (likely due to the small amount of extraliposomal bupivacaine present in the formulation) and at 12–24 hours after injection (resulting from the slow and prolonged release of bupivacaine from the DepoFoam). In contrast, bupivacaine HCl peaked once at 0.25–2 hours with a rapid decline toward zero. After wound infiltration, DB exhibited a  $t_{1/2}$  of 34.1 hours and a highest mean plasma  $C_{max}$  of 935 ng/mL (2- to 4-fold below bupivacaine's minimal toxicity thresholds), obtained after local administration of 600 mg DB.

**Conclusion:** DepoFoam bupivacaine exhibited pharmacokinetic properties consistent with a sustained-release formulation after a single injection. Plasma concentration remained well below bupivacaine's reported toxic levels, even with doses of DB up to 600 mg.

## INTRODUCTION

Figure 1. DepoFoam Multivesicular Liposome Technology




- Local anesthetics/analgesics are commonly used as part of a multimodal therapy for pain management
- Bupivacaine, which has been shown to reduce postsurgical pain when used via infiltration, is the longest acting local anesthetic/analgesic, but is limited to a duration of 7 hours or less<sup>1</sup>
- A medical need exists for a local anesthetic/analgesic that can extend the duration of pain relief following surgery
- DepoFoam® is a proven product delivery technology that encapsulates drugs without altering their molecular structure and then releases them over a desired time period (Figure 1); it is used in two commercially available products in the US and ex-US
- DepoFoam bupivacaine (DB) uses multivesicular DepoFoam technology to release bupivacaine over several days, providing up to 72 hours of pain relief

### Conventional vs Sustained-Release Formulations


- Conventional formulations reach maximum plasma concentration ( $C_{max}$ ) in a relatively short time period ( $T_{max}$ ). These pharmacokinetic (PK) parameters are consistent with a rapid onset of action, a high—and often times supratherapeutic— $C_{max}$ , and a relatively quick offset below the therapeutic threshold (Figure 2)

Figure 2. Release Profile of Conventional Formulations




- Sustained-release formulations are characterized by a lower overall  $C_{max}$  and a longer duration of action, but the increased  $T_{max}$  can result in a longer time to onset (Figure 3)

Figure 3. Release Profile of Sustained-Release Formulations




- A formulation that could marry the benefits of conventional and sustained-released delivery technologies while solving the challenges associated with each would address an unmet need in the multimodal pain management landscape (Figure 4)

Figure 4. The Ideal Formulation Would Provide a Rapid Onset and Sustained Duration of Action



- DB is formulated to provide the longer duration of efficacy and lower plasma concentration characteristic of sustained-release formulations, while also including extraliposomal bupivacaine for rapid absorption into the systemic circulation, thereby eliminating time to onset concerns
- As demonstrated in 2009 data presented at the International Anesthesia Research Society, a single administration of DB intraoperatively resulted in a comparable time to onset (5 minutes) to bupivacaine HCl, with sustained plasma bupivacaine concentrations in subjects undergoing inguinal hernia repair (Figure 5)

Figure 5. DepoFoam Bupivacaine Exhibits a Rapid Onset of Action and a Sustained Release<sup>2</sup>



## PURPOSE OF ANALYSIS

- To examine the PK parameters, including  $C_{max}$ ,  $T_{max}$ , and half-life ( $t_{1/2}$ ), of traditional bupivacaine compared with DB in order to determine whether DB exhibits PK parameters consistent with sustained-release formulations, including this bimodal distribution

## METHODS

- PK data from a total of 446 individuals receiving 75- to 750-mg of bupivacaine or DB across eleven Phase 1, 2, and 3 studies were analyzed
- Data were collected for multiple routes of drug administration, including wound infiltration, subcutaneous, epidural, and nerve block
- Various surgical models where DB was investigated in wound infiltration were studied, including:
  - Hemorrhoidectomy, hemiorrhaphy, bunionectiony, and total knee arthroplasty
  - A single injection of DB was given at the conclusion of the case

## RESULTS

- Independent of route of administration or surgical model studied, DB exhibited PK properties consistent with a bimodal release, as evidenced by the initial peak in plasma concentration due to the presence of extraliposomal bupivacaine, followed by the second, sustained release of the drug over a long  $T_{max}$ 
  - These data indicate DB can be used in a variety of soft tissue and bony surgeries
- Consistent plasma curves were observed for all doses of DB, suggesting that dosing can safely be adapted to meet the specific needs of each surgical model
- A small amount of extraliposomal bupivacaine is present in DB to allow for rapid absorption into the systemic circulation, this is represented by the initial peak in concentration seen for each study represented in the figure (Figure 6)
- A slow and prolonged release of bupivacaine from DepoFoam leads up to a second peak (the  $C_{max}$ ) occurring between 12 to 24 hours after administration; the  $t_{1/2}$  lasts up to 34.1 hours

Figure 6. Mean Plasma Concentrations of Bupivacaine After Administration of Various Doses of DepoFoam Bupivacaine or 100 mg of Bupivacaine HCl<sup>3</sup>




Table 1. Summary of PK Parameters for Bupivacaine After Administration of Single Doses of DepoFoam Bupivacaine or Bupivacaine HCl<sup>3</sup>

	DB				Bupivacaine
	120 mg ≤ 3 cm Incision	300 mg ≥ 3 cm Incision		600 mg Major Orthopedic/Reconstructive	100 mg ≥ 3 cm Incision
	Bunionectomy (N=26)	Hemorrhoid- ectomy (N=25)	Inguinal Hernia Repair (N=12)	Total Knee Arthroplasty (N=16)	Inguinal Hernia Repair (N=27)
C <sub>max</sub> (ng/mL)	166 (92.7)	867 (353)	365 (128)	935 (371)	336 (156)
T <sub>max</sub> (h)	2	0.5	12	36	0.6
AUC <sub>(0-t)</sub> (h•ng/mL)	5864 (2038)	16,867 (7868)	16,028 (5455)	58,717 (24,218)	4360 (1559)
AUC <sub>(inf)</sub> (h•ng/mL)	7105 (2283)	18,289 (7569)	16,758 (6288)	60,174 (25,117)	4372 (1560)
t <sub>1/2</sub> (h)	34.1 (17.0)	23.8 (39.4)	14.6 (4.64)	16.9 (4.78)	8.47 (2.89)

DB = DepoFoam bupivacaine; PK = pharmacokinetics.

Note: Arithmetic mean (standard deviation) except  $T_{max}$  (median).

### Threshold of Toxicity

- Even at a dose of 600 mg, the  $C_{max}$  of DB was 935 ng/mL, which is 2- to 4-fold below bupivacaine's minimal toxicity threshold
  - Levels of  $\geq 2000$  ng/mL of bupivacaine are where central nervous system effects are usually first seen<sup>4</sup>
  - Levels of  $\geq 4000$  ng/mL of bupivacaine are where cardiac system effects are usually first seen<sup>5</sup>

## DISCUSSION

- Although bupivacaine HCl is one of the most commonly used local agents for postsurgical analgesia, its 7-hour-or-less duration of action necessitates the use of additional therapeutics to manage pain
- DB builds upon the clinical experience of bupivacaine HCl and the well-established DepoFoam carrier matrix, providing a rapid onset of pain relief while extending the traditional duration of action to up to 72 hours
- The  $C_{max}$  following local administration of DB (300 mg) is comparable with that of bupivacaine HCl (100 mg) in all surgical models tested

## CONCLUSIONS

- Pooled data from eleven Phase 1, 2, and 3 clinical trials of DB illustrate a PK profile consistent with bimodal and sustained-release formulations
- An elongated  $T_{max}$ , greater  $t_{1/2}$ , and comparable  $C_{max}$  was demonstrated across multiple surgical models and various routes of administration
- Even at doses up to 600 mg, the mean maximal plasma concentration with DB is well within the safety threshold for bupivacaine

## REFERENCES

- Marcaine [package insert]. Hospira, Inc., Lake Forest, IL, 2009.
- White PF, et al. Pharmacokinetics of DepoBupivacaine following infiltration in patients undergoing two types of surgery and in normal volunteers. Poster presented at: 2009 International Anesthesia Research Society Annual Meeting; March 14–17, 2009; San Diego, CA.
- Data on file. Pacira Pharmaceuticals, Inc.; 2011.
- Kastrissios H, et al. *Eur J Clin Pharmacol*. 1993;44:555-557.
- Local Anesthetics That Metabolize to 2,6-Xyldine or o-Toluidine*. Research Triangle Park, NC: Integrated Laboratory Systems; Oct 2000.

Supported by funding from Pacira Pharmaceuticals, Inc.